Format

Send to

Choose Destination
Eur J Pharmacol. 2015 Dec 15;769:100-9. doi: 10.1016/j.ejphar.2015.11.003. Epub 2015 Nov 10.

Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways.

Author information

1
Department of Dental Pharmacology, School of Dentistry, Chonbuk National University, Jeonju 561-756, Republic of Korea.
2
School of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk 712-74, Republic of Korea.
3
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92037, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, CA 92037, USA. Electronic address: wgerwick@ucsd.edu.
4
Department of Dental Pharmacology, School of Dentistry, Chonbuk National University, Jeonju 561-756, Republic of Korea. Electronic address: ysoh@jbnu.ac.kr.

Abstract

Osteoclasts are unique bone remodeling cells derived from multinucleated myeloid progenitor cells. They play homeostatic vital roles in skeletal modeling and remodeling but also destroy bone masses in many pathological conditions such as osteoporosis and rheumatoid arthritis. Receptor activation of NF-κB ligand (RANKL) is essential to osteoclastogenesis. In this study, we investigated the effects of bromo-honaucin A (Br-H A) isolated from Leptolyngbya crossbyana (cyanobacterium). To investigate the mechanism of the inhibitory effect of Br-H A on osteoclastogenesis, we employed Br-H Ain RANKL-treated murine monocyte/macrophage RAW 264.7 cells for osteoclastic differentiation in-vitro. The inhibitory effects on in-vitro osteoclastogenesis was evaluated by counting the number of Tartarate resistant acid phospatase (TRAP) positive multinucleated cells and by measuring the expression level of osteoclast-specific genes like matrix metalloproteinase 9 (MMP9), cathepsin K (CATH K), GRB2-associated-binding protein 2 (GAB2), c-terminal myc kinase (C-MYC), C-terminal Src kinase (C-SRC) and Microphthalmia-associated transcription factor (MITF). Moreover, Br-H A blocked the resorbing capacity of RAW 264.7 cells on calcium phosphate-coated plates. Finally, Br-H A clearly decreased the expression of Akt and also decreased the activation of ERK. Thus, the study identifies Br-H A as potent inhibitor potentialin the treatment of diseases involving abnormal bone lysis such as osteoporosis, rheumatoid arthritis, and periodontal bone degradation.

KEYWORDS:

Akt; Br-Honaucin A; ERK; Osteoclastogenesis; RANKL; RAW 264.7; p38

PMID:
26550952
PMCID:
PMC4684412
DOI:
10.1016/j.ejphar.2015.11.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center